Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH

NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.

Kinjel Shah headshot

Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?

Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.

Sweta Killa headshot

5 S&P 500 Stocks That Zoomed 200% Plus From Pandemic Lows

After touching a low of 2,191 on Mar 23, 2020, the S&P 500 staged a strong comeback and is on track to hit a new milestone of 4,000.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $36, moving +1.32% from the previous trading session.

Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC

Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.

Sweta Killa headshot

1-Year Tour From Market Crash to Boom: 5 Top ETFs

The stock market staged a strong rebound from the lows and is currently hitting new highs with the major bourses crossing new milestones.

AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.

Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine

Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.

Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag

The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.

AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots

The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.

Pfizer (PFE) Gains As Market Dips: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $35.83, marking a +1.19% move from the previous day.

Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation

Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.

Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down

Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.

Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

J&J (JNJ) Outperforms the Industry Year to Date: Here's Why

J&J's (JNJ) shares are up this year mainly due to successful development of its COVID-19 vaccine.

Sweta Killa headshot

Air Travel Demand Nears 1-Year High: ETFs to Fly High

According to the latest data from Transportation Security Administration (TSA), about 1.357 million travelers checked in at American airports on Mar 12 - the highest number since Mar 15, 2020.

J&J (JNJ) COVID-19 Vaccine Gets WHO's Emergency Listing

J&J's (JNJ) single-shot COVID-19 vaccine gets Emergency Use Listing by the WHO, which will enable it to supply its vaccine to over 190 countries through COVAX facility.

Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.

AstraZeneca (AZN) Defends COVID-19 Vaccine Safety With Data

AstraZeneca (AZN) announces analysis of safety data of more than 17 million people vaccinated with its vaccine, demonstrating no increased risk of blood clot.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK

Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.

The Zacks Analyst Blog Highlights: UnitedHealth Group, Pfizer, International Business Machines, Humana and Exelon

The Zacks Analyst Blog Highlights: UnitedHealth Group, Pfizer, International Business Machines, Humana and Exelon

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Pfizer (PFE) closed at $34.93 in the latest trading session, marking a +1.39% move from the prior day.

Mark Vickery headshot

Dow Hits New All-Time High Close as Rescue Bill Passes

Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.

Sheraz Mian headshot

Top Analyst Reports for UnitedHealth, Pfizer & IBM

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Pfizer (PFE), and International Business Machines (IBM).

VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study

VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.